Nu-Med Plus Reports No Revenue and Increased Net Loss for Q1 2025

Nu-Med Plus, Inc. reported its financial results for the three months ending March 31, 2025, revealing no revenue for the period, consistent with the previous year. The company’s operating expenses decreased to $18,700 from $20,579 in the same quarter of 2024, primarily due to a reduction in professional and consulting fees. The net loss for the first quarter of 2025 was $19,933, a slight improvement compared to a net loss of $21,826 in the prior year. The company continues to operate without generating revenue as it remains in the development stage of its medical technologies.

As of March 31, 2025, Nu-Med Plus reported total assets of $5,173, which included $2,373 in cash and $2,800 in prepaid expenses. The company’s liabilities stood at $240,202, resulting in a working capital deficiency of $235,029. The financial statements indicate that the company has relied on shareholder loans and stock sales to cover its operational costs, highlighting the need for additional capital to sustain its business plan. Management anticipates requiring approximately $1.2 million over the next twelve months to support ongoing development and operational expenses.

Nu-Med Plus has not made significant strategic developments during the reporting period, as product development has been suspended pending a capital infusion. The company is focused on creating innovative nitric oxide delivery systems for medical applications, which are still in the early stages of development. The company has outlined plans for several products, including a hospital delivery device and a portable nitric oxide system, but has not yet submitted any for FDA approval. The lack of revenue and ongoing development challenges underscore the company's reliance on external funding to advance its product offerings.

The company’s employee headcount remains unchanged at 83,548,469 shares of common stock outstanding. Nu-Med Plus has not reported any significant changes in customer counts or user statistics, as it has yet to launch any products commercially. The company’s operational metrics indicate that it is still in the early stages of product development, with no current market share or product adoption rates to report.

Looking ahead, Nu-Med Plus acknowledges that its current cash reserves are insufficient to execute its business plan, raising substantial doubt about its ability to continue as a going concern. The company is actively seeking additional funding through equity sales and loans from shareholders to support its operations and product development efforts. Management has indicated that without securing further financing, the company may face challenges in maintaining its operations and advancing its product development initiatives.